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Policy Forum
O
thers have made the point 
convincingly that Millennium 
Development Goal 4, a 
reinvigorated commitment to reduce 
child mortality by two-thirds before 
2015, could be achieved if existing 
interventions were implemented on a 
massive scale [1,2]. Widespread access 
to simple therapeutic interventions, 
in accordance with World Heath 
Organization (WHO) case 
management guidelines, is a substantial 
part of this package. Assuming that 
the coverage of existing interventions 
can be improved, what will be the 
next major challenge? We believe it 
will be enabling groups of countries, 
individual countries, or even large 
states to take increasing responsibility 
for the future of their case 
management strategies. Here we bring 
together insights from a wide range 
of disciplines to propose a framework 
for national surveillance, monitoring, 
and research that could help inform 
guideline development in low-income 
settings. Although our focus is on 
childhood illness, the principles might 
be applied more widely.
The History of Case Management 
Guidelines
WHO guidelines for common 
childhood illnesses were developed 
over several decades. A high burden of 
disease in settings with basic biomedical 
health systems demanded management 
strategies that were simple, safe, and 
inexpensive to achieve high coverage. 
Often the aim was high diagnostic 
sensitivity at the expense, to a degree, 
of specificity. However, much of the 
research underpinning the actual 
content of current guidelines was 
undertaken in the 1980s and early 
1990s, and often considerable reliance 
was placed not on evidence but on 
expert opinion [3,4]. Three factors 
now undermine the relevance of this 
foundation.
1. Changing disease patterns. In
several developing countries, the 
incidence of malaria is falling sharply 
as health services achieve high coverage 
with insecticide-treated bed-nets 
and artemisinin-based combination 
therapies [5,6]. The introduction of 
the pneumococcal conjugate vaccine 
over the next decade, in addition to the 
conjugate vaccine against Haemophilus
influenzae type b, will dramatically 
reduce the incidence of serious 
bacterial pneumonia in children [7–9]; 
meanwhile, the incidence of asthma is 
rising. Newer vaccines, urbanisation, 
infrastructure development, and 
poverty reduction strategies will 
all potentially further alter the 
epidemiology and relative burden of 
childhood diseases. 
2. Health systems are heterogeneous 
and evolving differently. Economic, 
social, and political developments 
are far from uniform across or even 
within low-income countries, and the 
capacities of their health systems vary 
commensurately. For example, the 
number of physicians per 100,000 
population varies 10-fold even within 
Africa [10], and large variations exist in 
the scale and scope of the private health 
sector and the use of community health 
workers. Variability in health-seeking 
behaviour, access to care, types of 
service provider, and skill sets of health 
workers may all need to be taken into 
account in developing guidelines. For 
example, differentiating pneumonia 
from asthma may depend on a health 
worker’s level of training. 
3. New technologies demand 
new thinking. Rapid technological 
innovation is producing an array of 
new diagnostics. While they have 
considerable potential to improve care 
[11], this potential may not always be 
realised. In Tanzania, introduction of a 
rapid, point-of-care malaria diagnostic 
did not reduce rates of malaria 
treatment for children with negative 
test results [12]. Thus, performance of 
new diagnostics may not be the same in 
the field as it is in carefully controlled 
clinical or laboratory tests for both 
technical and human reasons. We may 
seriously overestimate the effectiveness 
and cost-effectiveness of guidelines by 
failing to account for this discrepancy 
[13].
The Science of Guideline 
Development
The science of guidelines is a 
relatively new discipline [14] that 
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seeks to combine clinical, behavioural, 
and implementation research. New 
institutions such as the National 
Institute for Health and Clinical 
Excellence (http://www.nice.org.
uk/) and the Agency for Healthcare 
Research and Quality (http://www.
ahrq.gov/) have arisen to evaluate 
the population benefits of novel 
therapies. WHO has adopted this 
new science. In a 2006 journal 
supplement, WHO commissioned 16 
reports to enunciate best practices 
for each step and methodology 
underpinning guideline development 
(http://www.health-policy-systems.
com/articles/browse.asp?volume=4). 
We now illustrate some consequences 
of these changes in developing new 
guidelines for sick children. 
1. Disease problems and therapeutic 
options. The National Institute for 
Health and Clinical Excellence 
stresses the importance of a complete 
description of the problem tackled 
by guidelines [15]. For common 
childhood diseases in low-income 
countries, the relevant starting point 
is the child who develops a given 
symptom. For a population of such 
children, descriptive models can be 
developed to follow every possible 
course through access to care, 
diagnosis, treatment, and outcome and 
are elaborated as decision trees (see 
Figure 1 for a simple example). This 
form of population-level modelling 
has long been used in preventive 
interventions [16], in economic 
evaluation [17], and in clinical 
decision analysis [18]; recently, it has 
been used to evaluate the potential of 
new diagnostics [9,13]. However, its 
potential to answer questions about 
health systems as a whole has so far 
been largely ignored.
Examining a complete model 
reveals how each step in a chain of 
events may be important and exposes 
unanticipated gaps in our evidence 
base. For example, a systematic 
review of the efficacy of oral therapy 
in pneumonia may provide robust 
evidence to guide one decision node, 
but effectiveness is dependent on the 
accuracy of health workers in classifying 
childhood pneumonia at this node. 
The right antibiotic given to the wrong 
patient does not constitute effective 
treatment.
The real power of these models, 
therefore, is in their ability to 
sum outcomes, favourable and 
unfavourable, for multiple scenarios 
represented by the proportion of the 
population of sick children moving 
down each of the possible linear 
paths. Building the model requires 
specification of the pathways to be 
considered and estimation of the 
probabilities that any fork in the 
path will be followed. By collecting 
appropriate information, we can 
therefore begin to understand how a 
guideline will affect health outcomes 
across an entire population. At nodes 
where data are scarce, sensitivity 
analyses can be conducted, varying the 
values incorporated at different points 
in the model within ranges based on 
available data or clinical plausibility. 
By varying the values used in models 
we can also help identify the key 
decision points and target research 
and resources at points that lead to the 
greatest overall benefit. 
2. Constructing decision tree models. 
The purpose of a model structure 
for guidelines is to facilitate decision 
making. In theory, guidelines reduce 
the latitude of clinical decisions by 
taking them out of the hands of health 
workers and placing them in the hands 
of a higher authority; but who should 
that authority be? Traditionally it has 
been WHO because guidelines have 
been created to apply to all low-income 
countries while tending to ignore their 
heterogeneity, a limitation WHO itself 
has already recognised. Actual policy 
decisions on guidelines are taken at 
country or even state level. These 
decisions are guided by: (a) The local 
incidence and aetiology of disease, and 
the prevalence of disease-modifying 
factors such as HIV; (b) National 
rates of uptake and coverage of new 
interventions such as bed-nets and 
vaccines; and (c) The organisation and 
capacity of a country’s health system. 
To accommodate variation, therefore, 
decision models of childhood disease 
syndromes should incorporate the best 
available evidence and, where possible, 
reflect what is known about the local 
context. This does not mean that each 
county requires its own unique model. 
Generic approaches could be adapted 
for groups of countries, a single 
country, or even a single state in two 
major ways. Firstly, local data may be 
preferred in comparative assessments of 
alternative interventions and secondly, 
the models may be made more or 
less sophisticated reflecting both the 
complexity of the local situation and 
the availability of data. For example, 
models might incorporate treatment 
for Pneumocystis pneumonia based 
either on immediate HIV testing or on 
an empiric approach in cases of severe 
or very severe pneumonia.
This population modelling 
perspective is closely analogous to that 
of the policy maker who considers the 
net benefit to society when making 
decisions. Consequently, guidelines 
supported by decision tree models 
should be accessible to policy makers, 
especially if they incorporate local data 
on disease and context. Consider the 
example of a febrile child presenting 
to a health facility in Africa. What is the 
risk inherent in abandoning the policy 
of universal treatment with an anti-
malarial drug when the true prevalence 
of malaria falls to, for example, one 
per hundred? Does the risk become 
acceptable if we introduce a rapid 
screening test with a sensitivity of 0.9? 
To what degree does minimising risks 
depend on good access to care and a 
health worker’s capacity to arrange for 
review if symptoms persist or worsen 
(watchful waiting)? Such looming 
questions will be best answered 
by representative data on malaria 
prevalence and access to services and 
by local policy makers. There may 
be surprising results. For example, 
improving access to health care may 
turn out to be more effective and less 
expensive than introducing a new 
intervention. It is also possible to use 
these models to examine and compare 
the estimated effects of disease 
prevention strategies [19] that reduce 
the total number of cases entering the 
case management “pipeline.”
3. Incorporating data on cost. 
Decisions on health care provision 
are always political and result in 
changes in cost to the provider, the 
patient, the population, or some 
combination of the three. Information 
on costs, including opportunity costs, 
is therefore a key element in decision 
making. Incorporating cost data also 
promotes transparency and protects 
against vested interests by illuminating 
the costs and consequences of 
alternative decisions. Unfortunately 
there are still very few local, basic 
cost data to incorporate into decision 
making, despite the efforts of WHO 
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others. It should not be so difficult, 
from the provider perspective, to 
obtain appropriate data on, for 
example, the average “hotel” cost of 
a hospital day or the average cost of 
providing a primary care facility or a 
community health worker through 
which services are delivered. These 
types of data, when combined with 
service utilisation data (also often 
unavailable; see below), are essential to 
understanding the cost-effectiveness of 
programmes and should be quantified 
and made available by governments, 
donors, non-governmental 
organisations, and others.
4. Recognising the human factor. 
Models of preventive interventions, 
such as vaccines, include parameters 
for vaccine effectiveness and vaccine 
coverage as primary data inputs. 
These data are gleaned from large-
scale clinical trials and national 
surveys. Models of clinical guidelines 
also require data on the size of the 
intervention effect and the degree 
of coverage. However, they must also 
recognise that providers and recipients 
of health care do not or cannot always 
follow guidelines [12,20]. Research 
data on adherence and compliance in 
low-income settings are scarce [14,21], 
but health workers may be subject 
to a variety of external and personal 
interests that affect their practice. 
More generally, the “patient” is usually 
a somewhat abstract concept in the 
development of public health policies 
or guidelines. This makes it relatively 
acceptable to introduce guidelines 
that will fail a small proportion of all 
patients in the interests of doing the 
best for the large majority. Health 
workers, however, may reject such a 
guideline in the clinic because they 
are unwilling to pass on even a small 
risk to the population of patients 
they see. To counter this concern, 
models provide an effective means 
to communicate how rather abstract 
population benefits, such as delaying 
the development of antibiotic 
resistance, are affected by individual 
patient decisions like withholding 
antibiotic treatment. They also provide 
a means of assessing whether investing 
in adherence or compliance might 
be as effective as introducing new 
interventions. To understand the need 
for improved adherence or compliance 
doi:10.1371/journal.pmed.0050241.g001
Figure 1. Simple Conceptual Framework for a Pneumonia Case Management Guideline, Based on Current WHO Advice, Illustrating Some of 
the Areas For Which Improved Global and Local Data Could Improve Understanding of Likely Policy Effectiveness 
Contextual factors are likely to operate from the stage at which they first appear on the left-hand side of the figure right through to the far right of 
the figure. The list shown is illustrative and not exhaustive.
Consider the possible effects of introducing Haemophilus influenzae type b and pneumococcal conjugate vaccines. As the relative prevalence of 
bacterial pneumonia declines, the positive predictive value of any imperfect clinical or diagnostic test used to assign children to antibiotic treatment 
will also fall, and so the population benefits of antibiotic therapy will also decline. This will increase the proportion of unnecessary treatments and 
enhance the importance of adverse effects at both the individual and population levels.
Population adverse effects, for example the development of resistance, are likely to reflect total antibiotic use and can be included as additional 
probabilities associated with each treatment episode. For clarity these are not shown in the illustration but see [11] for an example.
The effect of our current lack of basic data may be illustrated when we try to estimate the value of new treatments in a new setting. In the last ten 
years, most emerging evidence has come from comparative efficacy trials of primary treatments for pneumonia. However, while we now have data 
on the relative reduction in risk of treatment failure or mortality attributable to a new therapy, we cannot estimate absolute risk reduction at a specific 
country level because data on the risk of treatment failure or death associated with the “old” treatment in this setting are missing.
Consider also recent calls from paediatricians in areas with a high prevalence of HIV for changes in the guidelines on treating hospitalised infants 
with severe pneumonia. If we know baseline risks, the incremental effectiveness of any newly proposed treatment, and the prevalence of HIV, we can 
estimate the aggregate outcomes of changing treatment for a given population. Additionally, the net benefits of such a change could be compared 
with alternative interventions elsewhere in the decision tree, such as changing the antibiotic used for outpatient treatment of pneumonia.PLoS Medicine  |  www.plosmedicine.org 1668 December 2008  |  Volume 5  |  Issue 12  |  e241
in a setting demands some form of 
measurement. How many regions have 
any indicative data on whether their 
guidelines are actually followed? 
5. Investing in local data. Global
burden of disease estimates are 
attracting much research attention. 
While initiatives such as the Health 
Metrics Network (http://www.who.
int/healthmetrics/) aim to improve 
national health information systems, 
most countries are still unable to 
answer a simple question such as: 
“How many children with pneumonia 
are treated and die annually in 
hospital?” In a recent high-profile 
global modelling exercise, pneumonia 
case fatality rate estimates were based 
on only four published studies [11]. 
How can we quantify the absolute 
benefits of new interventions compared 
with “standard” treatment in a given 
country unless we know the baseline 
incidence of disease, risk of treatment 
failure, and case fatality rates? For 
example, consider a new antibiotic 
regimen for very severe pneumonia 
that is proven in large randomised 
controlled trials to reduce mortality 
risk by 25%. This relative benefit will 
result in very different absolute benefits 
where baseline case fatality rates for 
very severe pneumonia are 4% and 
20%. In the former case, for every 100 
children treated with a new, possibly 
expensive antibiotic one child death is 
averted, while in the latter case five are 
averted—dramatically influencing cost-
effectiveness.
If we really wish to understand the 
potential impact of new interventions 
and policy decisions, there is an 
immediate need for basic community, 
clinical, and epidemiological data. 
Much of this data ought to be produced 
routinely by functional health systems. 
If data are unavailable or unreliable, 
then we should purposefully collect 
them at representative sentinel sites. In 
future, we should consider a handful 
of studies from across the globe 
inadequate to estimate important 
parameters such as the incidence 
of disease or the case fatality ratio. 
Data on disease burden can then be 
integrated with complementary data on 
costs, health systems, access to care, and 
coverage of interventions. The process 
of collecting and analysing these data 
should be co-ordinated increasingly by 
local public health institutions as part 
of parallel regional or national capacity 
building. This is essential if individual 
countries are to reap long-term benefits 
from better policy decisions.
A Role for WHO
The development of WHO’s first 
generation of simple case management 
guidelines represented the culmination 
of considerable formative research, and 
their impact has been considerable. 
However, no comprehensive process 
for evaluation, revision, or refinement 
was established at introduction, 
despite the fact that they are applied 
globally to hundreds of millions of 
episodes of pneumonia, diarrhoea, 
and malaria every year [22–24]. As the 
epidemiological landscape diversifies 
we will need appropriate evidence 
to adapt treatment guidelines for 
these millions of children so that the 
guidelines are optimally effective at 
regional or country, not continental, 
level. Strengthening this process may 
foster, through increased ownership, a 
virtuous cycle that generates demand 
for better data and improves the value 
and specification of models. As a 
starting point, models should be used 
to identify quickly those decision points 
and data that are most critical to the 
determination of costs and outcomes. 
The transition to a more informed 
process of guideline development will 
take time. WHO is ideally positioned, 
however, to assist countries in an 
increasingly devolved process of 
decision making. It would be a 
retrograde step if each setting began 
to demand use of only its own data 
(and not what we are recommending). 
Systematic reviews of the evidence and 
strategically conducted research will 
be the most appropriate and efficient 
means to produce estimates for many 
model parameters. WHO should play 
an important role in providing such 
global evidence. We have argued that 
the value of guidelines will increasingly 
also depend on the quantity and 
quality of local data informing 
their development. Standardising 
and monitoring the collection and 
reporting of data coming from routine 
health system monitoring or targeted 
surveillance approaches would be of 
huge benefit, permitting data sharing 
across areas, and could be undertaken 
by WHO and its regional offices. 
Development of generic tools and 
analytical approaches allied to capacity 
building of local institutions would 
allow WHO and partners to foster 
progressively greater local responsibility 
for use of data and improvements 
in its scope and quality. WHO could 
share lessons learned and engage with 
international agencies to promote and 
provide unrestricted access to high-
quality data. 
Conclusion
We have heard many calls for, and seen 
considerable resources devoted to, 
improving data to inform often vertical 
global health monitoring exercises. 
In order to determine health policy, 
industrialised countries are investing 
in systems to acquire their own data on 
the burden of diseases and the costs of 
interventions. This is not an expression 
of nationalism but a recognition that 
diseases and health systems vary across 
and even within countries. As low-
income countries develop, they will also 
desire local data for this purpose to use 
in conjunction with other data available 
from international collaboration or 
synthesis. The question that we have 
posed is: how do we anticipate this 
need and its consequences for the 
evolution of health systems in low-
income countries? We have argued 
that two simple approaches will carry 
this forward: the development of 
population-based models of health 
systems and the acquisition of relatively 
simple local data on the burden of 
disease, the effectiveness of simple 
curative practices, their cost, and 
pattern of usage. The models proposed 
combine international and local data 
and could lead, in turn, to a greater 
demand by policy makers for more 
and better data. Given the economic 
constraints it will be necessary to 
share data across regions for some 
time, especially the findings of major 
research studies. Initial investment 
in local health data will be required 
to foster the evolution of guidelines 
and policy in low-income countries. 
This challenges us to strengthen our 
support for clinical health systems 
research at country level, within 
ministries of health, and in public 
service and academic institutions. 
Low-income countries will need 
better trained epidemiologists, health 
economists, clinical epidemiologists, 
and behavioural and laboratory 
scientists who are able to gather, utilise, 
and interpret data from their region. 
The responsibility for this lies with all PLoS Medicine  |  www.plosmedicine.org 1669 December 2008  |  Volume 5  |  Issue 12  |  e241
involved in improving global health 
and also depends on the countries 
themselves who, by application of 
simple health system models, create the 
demand for better care through better 
data.  
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